Horizon Discovery Group’s molecular reference standards integrated into QIAGEN GeneReader NGS System
Deal demonstrates the impact Horizon's Reference Standards are having in supporting the rapidly growing Next Generation Sequencing (NGS) market.
Horizon Discovery Group has announces that QIAGEN NV will be offering an extensive package of quality control data, generated through the application of Horizon’s Reference Standards, with its GeneReader NGS System.
As part of the project, QIAGEN thoroughly validated its platform using Horizon’s Molecular Reference Standards. The very high levels of consistency seen provided QIAGEN with the confidence to use Horizon’s Standards to generate their data set.
By incorporating this data set into the GeneReader NGS System workflows, QIAGEN is able to reinforce the proven accuracy of its NGS platform, facilitating system setup, quality assurance and training for laboratories.
Further, QIAGEN’s GeneRead QIAact Actionable Insights Tumor Panel is the first in a family of multiplex panels for the GeneReader NGS System targeting the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma. The accuracy, consistency and reliability of this Panel was validated through extensive testing compared with the control data derived from Horizon’s Reference Standards, proving its performance.
Dr Paul Morrill, President, Products Business, Horizon Discovery Group, commented: “The incorporation of Horizon’s widely-used and well-established Reference Standards as a data set into the GeneReader NGS workflow reinforces the critical role that they play in the adoption of NGS workflows by clinical research laboratories.” He continued: “As the GeneReader and its associated panels are adopted, we anticipate that, in addition to their use as the basis of this data set, our Reference Standards will be used to support ongoing quality control in many labs, and we look forward to continuing to collaborate with QIAGEN as work continues to unlock the full potential of both technologies.”
“We created the GeneReader NGS System to provide the world’s first truly complete solution for next-generation sequencing,” said Jonathan Arnold, QIAGEN’s Oncology Franchise Business Leader. “The excellent quality and consistency of Horizon’s Reference Standards has allowed for the generation of a powerful data set. Their integration into the GeneReader NGS System makes quality assurance easier for users – from system set-up and training laboratory staff to supporting the ongoing quality control of NGS workflows.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance